Social Determinants of Health & Clinical Trial Access

Posted on: Friday 20 November 2026

This blog article has been prepared by Dr Anas Malik Radif Alubaidi, member of the New Technologies Expert Group and EDI Forum.

 

The article presents the views of the author and not necessarily those of the Faculty of Pharmaceutical Medicine (FPM).

Introduction:

Social Determinants of Health (SDOH) significantly influence an individual’s ability to participate in clinical research. Factors such as socioeconomic status, education, transportation, healthcare access, and digital literacy can create barriers that limit recruitment and retention of diverse populations. Addressing these challenges is essential to ensuring equitable access to clinical trials, improving the representativeness of study populations, and generating evidence that better reflects real-world patient communities. Pharmaceutical physicians, sponsors, and research teams play a critical role in developing inclusive strategies that reduce disparities and advance health equity in clinical research.

Understanding SDOH:

SDOH are the non-medical factors that influence health outcomes and an individual’s ability to access healthcare services, including clinical research opportunities. These factors include socioeconomic status, education, employment, housing, transportation, social support, and access to technology. Understanding SDOH is essential in clinical research because they can significantly affect trial awareness, enrolment, participation, and retention, ultimately influencing the diversity and representativeness of study populations (CDC, 2026).

SDOH are the non-medical factors that influence health outcomes and an individual’s ability to access healthcare services, including clinical research opportunities.

How SDOH Influence Clinical Trial Participation:

SDOH influence clinical trial participation at every stage of the research journey, from awareness and recruitment to retention and study completion. Individuals with lower socioeconomic status may be unable to take time off work, afford childcare, or absorb lost wages associated with study visits. Limited transportation options can make travel to research sites difficult, particularly for participants living in rural or medically underserved areas.

Educational attainment and health literacy also play important roles. Complex informed consent documents and study procedures may be challenging for individuals with limited health literacy, reducing willingness to participate. Language barriers can further limit understanding of trial requirements and available opportunities.

Access to healthcare affects recruitment because many participants are identified through healthcare systems. Individuals with limited access to healthcare services may never learn about relevant clinical trials.

Additionally, increasing reliance on digital technologies for recruitment, electronic consent, telehealth visits, and remote monitoring may unintentionally exclude individuals with limited internet access, inadequate digital literacy, or lack of suitable devices.

These barriers contribute to the underrepresentation of certain populations in clinical research, reducing the diversity of study populations and limiting the generalisability of findings to real-world patient communities (CDC, 2026).

Strategies to Improve Access:

Improving equitable access to clinical trials requires targeted interventions that address specific SDOH-related barriers. Research sponsors and study sites can provide transportation vouchers, rideshare services, or reimbursement for travel expenses to reduce transportation challenges. Flexible scheduling, extended clinic hours, and compensation for participant time can help individuals balance trial participation with work and family responsibilities.

Community-based recruitment through local healthcare providers, faith-based organisations, community centres, and patient advocacy groups can improve trust and awareness among historically underrepresented populations. Employing culturally competent research staff and providing study materials in multiple languages can further enhance participant engagement.

To address health literacy barriers, consent documents should be written in plain language and supplemented with visual aids and educational sessions. Patient navigators can guide participants through study requirements, appointment scheduling, and regulatory processes.

For decentralised and hybrid clinical trials, sponsors should consider providing internet-enabled devices, technical support, and digital literacy training when necessary. Remote monitoring, home-health visits, telemedicine consultations, and electronic patient-reported outcomes can reduce participation burden while maintaining study quality and regulatory compliance.

Collectively, these strategies can improve recruitment, retention, and representation, helping clinical trials better reflect the populations most affected by disease (NCATS, 2024).

To address health literacy barriers, consent documents should be written in plain language and supplemented with visual aids and educational sessions. Patient navigators can guide participants through study requirements, appointment scheduling, and regulatory processes.

Future Directions for Equitable Clinical Research:

The future of equitable clinical research lies in integrating community engagement, patient-centred trial designs, and innovative digital technologies to reduce barriers to participation. Expanding decentralised clinical trials, strengthening partnerships with underserved communities, and improving access to telemedicine and digital tools can help ensure broader representation in research. These efforts are essential for generating more inclusive evidence, improving health equity, and ensuring that clinical trial results are relevant to diverse real-world populations (NCATS, 2024) (NCATS, 2026).

References

  1.  Centers for Disease Control and Prevention (CDC) (17th August 2026). Social Determinants of Health. NCHHSTP Health Equity. Available at: https://www.cdc.gov/health-disparities-hiv-std-tb-hepatitis/about/social-determinants-of-health.html. Accessed on: 15th October 2026.
  2. National Center for Advancing Translational Sciences (NCATS) (10th June 2024). NCATS Report Highlights Decentralized Clinical Trials’ Challenges, Opportunities. Available at: https://ncats.nih.gov/news-events/news/ncats-report-highlights-decentralized-clinical-trials-challenges-opportunities. Accessed on: 15thOctober 2026.
  3. National Center for Advancing Translational Sciences (NCATS) (23rd January 2026). Community Engagement Across the CTSA Program Consortium. Available at: https://ncats.nih.gov/research/research-activities/ctsa/projects/community-engagement. Accessed on: 15th October 2026.
Disclaimer: AI tools were used during the initial planning stages of this article solely to provide suggestions regarding the wording of the article title and potential section headings for organising the topic. The manuscript’s content, analysis, discussion, interpretations, conclusions, and references were written entirely by the author. All information presented in this article was independently reviewed, developed, and approved by the author. AI was not used to generate the body of the manuscript, formulate scientific conclusions, or express the author’s professional opinions.